Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/9/2026

1. SPY
2. USO
3. META
4. MSFT
5. MU
6. COST
7. IONS
8. AVAV
9. SKHY
10. ORCL

Go back to Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
EMERGENT BIOSOLUTIONS, Inc. (NYSE: EBS) Delayed: 8.18 +0.04 (0.49%)
Previous Close $8.14    52 Week High $44.38 
Open $8.14    52 Week Low $24.47 
Day High $8.37    P/E 409.00 
Day Low $8.04    EPS $0.02 
Volume 644,212